Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Joint Biosciences (Sh) Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's active prosecution is restricted to 1 distinct examiner and 1 distinct art unit, indicating a very specific scope of review. In the complex biotechnology sector, this concentration suggests that the company is currently focusing its resources on a single, critical innovation. For the practitioner, this means that the immediate success of the company's patent strategy depends on the resolution of this single pending matter, with no other active applications to diversify the prosecution risk.
LY, KRISTINA ELISABETH is the busiest examiner, overseeing 1 busiest examiner pending action. This action constitutes the total 1 pending office action for the company, meaning the current prosecution outcome depends on the evaluation of this single examiner. The fact that the busiest examiner handles the only pending action highlights a period of singular focus for the company. A successful outcome will require a response strategy that is specifically tailored to this examiner's concerns, as there are no other pending actions to provide alternative opportunities for securing patent protection in this field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412784 | ONCOLYTIC VIRUS AND USE THEREOF | LY, KRISTINA ELISABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412784 | ONCOLYTIC VIRUS AND USE THEREOF | LY, KRISTINA ELISABETH | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18412784 | ONCOLYTIC VIRUS AND USE THEREOF | LY, KRISTINA ELISABETH | 1671 | §103§112Other | Non-Final OA | — | Pending | Jan 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJoint Biosciences (Sh) Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kristina Elisabeth Ly has the most, with 1 of Joint Biosciences (Sh) Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.